Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

Published:2016-10-25 Issue:10 Volume:23 Page:2414-2422
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Pietrantonio Filippo,Vernieri Claudio,Siravegna Giulia,Mennitto Alessia,Berenato Rosa,Perrone Federica,Gloghini Annunziata,Tamborini Elena,Lonardi Sara,Morano Federica,Picciani Benedetta,Busico Adele,Volpi Chiara Costanza,Martinetti Antonia,Battaglin Francesca,Bossi Ilaria,Pellegrinelli Alessio,Milione Massimo,Cremolini Chiara,Di Bartolomeo Maria,Bardelli Alberto,de Braud Filippo

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review;Journal of Personalized Medicine;2024-07-15

2. Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data;ESMO Real World Data and Digital Oncology;2024-06

3. A panorama of colon cancer in the era of liquid biopsy;The Journal of Liquid Biopsy;2024-06

4. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road;Frontiers in Pharmacology;2024-04-22

5. Structure–Activity Relationship Study of (E)-3-(6-Fluoro-1H-indol-3-Yl)-2-methyl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (FC116) Against Metastatic Colorectal Cancers Resistant to Oxaliplatin;ACS Pharmacology & Translational Science;2024-04-12